I'm thrilled to sit down with Ivan Kairatov, a renowned biopharma expert whose extensive experience in research, development, and innovation has positioned him as a thought leader in the cell and gene therapy (CGT) industry. With a sharp focus on emerging technologies and strategic growth, Ivan
The realm of cell and gene therapies (CGTs) has long been heralded as a revolutionary frontier in medicine, promising transformative outcomes for patients with previously untreatable conditions, yet it faces significant hurdles in securing consistent funding. As the industry matures, it confronts a
In the realm of regenerative medicine, a staggering challenge persists: millions of patients worldwide suffer from vascular diseases, awaiting solutions that can repair or replace damaged blood vessels, while endothelial cells, which form the critical inner lining of these vessels, hold the key to
Imagine a world where damaged hearts mend themselves, where neurodegenerative diseases like Parkinson’s are no longer a life sentence, and where spinal cord injuries don’t mean a lifetime of immobility. Stem cell therapies, particularly those derived from pluripotent stem cells (PSCs), are poised
I'm thrilled to sit down with Ivan Kairatov, a renowned expert in biopharma with a wealth of experience in research and development, particularly in the rapidly evolving field of cell and gene therapies (CGTs). With his deep knowledge of technology and innovation in the industry, Ivan offers unique
In the rapidly evolving realm of advanced therapy medicinal products (ATMPs) and complex biologics, the promise of transforming patient care is both exhilarating and daunting, as these cutting-edge treatments hold the potential to address some of the most pressing unmet medical needs, from rare
